Guangzhou Henovcom Biosciences Co., Ltd.

Pipeline

研发管线

View Details

Business cooperation

业务合作

View Details

Contact

联系我们

View Details

ABOUT US

关于我们

Development

Leadership

Our culture

Honor

About us

Guangzhou Henovcom Bioscience Co., Ltd. was founded in 2013 by biopharmaceutical veterans with extensive experience in the US biopharmaceutical industry R&D and regulatory agencies. The founders have participated in the discovery and development of several marketed blockbuster drugs.

View Details

News and information

3rd mRNA Based Therapeutics Summit USA

2023-07-19

Venue: Boston Convention and Exhibition Center Date: Jul 26, 2023 - Jul 28, 2023 The mRNA Based Therapeutics Summit, the important, authoritative, and comprehensive premier forum, will hold its third session in Boston in July this year. Many experts and company executives in the industry will attend to introduce the latest developments in mRNA pipelines, share mRNA technology breakthroughs, and demonstrate mRNA-related products.

【Reprint】AI, mRNA vaccine...experts eye latest biomedicine trends in GZ

2023-05-30

“Currently, AI is being used to assist in the diagnosis of cancer patients’ very serious infections, organ transplantation, and situations of patients in intensive care units, as well as fungal infections of the skin, nails, and hair, as well as systemic function. Therefore, the goal is to increase both the speed and accuracy of diagnosis.” Malcolm Richardson, Chief Scientist of Richardson Bio-Tech, told GDToday during the first Guangzhou International BioPharm Conference.

Breakthrough in patent lockdown! Henovcom's self-developed mRNA cap analogues have been patented for protection

2023-05-23

Recently, Henovcom Biosciences Co., Ltd. received the Notice of Patent Grant from the China National Intellectual Property Administration on "Compounds for RNA capping and their applications (Patent No.: ZL202210973168.5)". This invention patent relates to the compound structure and application of a cap1 cap analog for co transcription capping. Furthermore,this is the first authorized patent in China for the structure of mRNA co-transcription capping analogs. Besides Chinese invention patents, Henovcom has started to expand its presence in other major market countries through the PCT approach.

GMP Workshop of Nucleotide Raw Material of Henovcom officially put into operation

2023-01-04

In the morning of January 3rd, the opening ceremony of the GMP workshop of Nucleotide Raw Materials of Henovcom was successfully held. This marks the official opening of Henovcom’s production workshop, which officially started construction in July 2022 and took nearly half a year to finish. The workshop has a building area of 2300 square meters with multiple functional areas throughout the entire professional process, including research and development laboratories, pilot scale workshops, production workshops (D-level clean areas),

3rd mRNA Based Therapeutics Summit USA2023-07-19 【Reprint】AI, mRNA vaccine...experts eye latest biomedicine trends in GZ2023-05-30 Breakthrough in patent lockdown! Henovcom's self-developed mRNA cap analogues have been patented for protection2023-05-23 GMP Workshop of Nucleotide Raw Material of Henovcom officially put into operation2023-01-04